GANETESPIB (NON-SMALL CELL LUNG CANCER) - FORECAST AND MARKET ANALYSIS TO 2022
Executive Summary

Ganetespib: Key Metrics in NSCLC Markets

<table>
<thead>
<tr>
<th>2022 ganetespib Sales</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>US</td>
<td>$23.75m</td>
</tr>
<tr>
<td>5EU</td>
<td>$2.46m</td>
</tr>
<tr>
<td>Japan</td>
<td>$14.69m</td>
</tr>
<tr>
<td>China</td>
<td>NA</td>
</tr>
<tr>
<td>India</td>
<td>NA</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>$40.90m</strong></td>
</tr>
</tbody>
</table>

Key Events (2012–2022) | Level of Impact
---|---
Approval/launch of ganetespib in the US in 2016 | ↑↑
Approval/launch of ganetespib in the 5EU & Japan in 2016 & 2017 respectively | ↑

Source: GlobalData

5EU = France, Germany, Italy, Spain, and UK; 7MM = US, 5EU, and Japan
NA: Not Available

Sales for ganetespib in the Global NSCLC Market

Ganetespib sales are expected to increase from $3.17m upon launch in 2016 to $40.90m in 2022 from sales in the US, 5EU and Japan.

Key factors affecting the uptake of ganetespib will include:

- Improved toxicity profile compared with first-generation Hsp90 inhibitors
- First-in-class targeted therapy with a unique mechanism of action in NSCLC
- Ganetespib will likely compete against the established therapies Alimta and Avastin in non-squamous patients as well as the emerging pipeline therapies onartuzumab, ramucirumab, custirsen and nintedanib.

- Ganetespib’s late entry into the second line crowded market will encumber its uptake.

The below figure illustrates the sales of ganetespib for NSCLC in the seven major markets during the forecast period.

Ganetespib Sales for NSCLC by Region, 2022

<table>
<thead>
<tr>
<th>Region</th>
<th>Sales Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>US</td>
<td>58%</td>
</tr>
<tr>
<td>5EU</td>
<td>36%</td>
</tr>
<tr>
<td>Japan</td>
<td>6%</td>
</tr>
</tbody>
</table>

Total: $40.90m

Source: GlobalData
**Executive Summary**

**What Do the Physicians Think?**

“There are a lot of unmet medical needs for squamous [non-small cell lung cancer] because we have not so many possibilities to treat the patients. And also, we have made progress in [the] first line [for non-squamous patients] with Avastin and with TKIs, but [in the] second and third line, we have no very effective treatment [for non-squamous patients], so a lot of unmet medical needs are there.”

OUS KOL, March 2013

“[For access to new drugs,] I think it will depend on the magnitude of the benefit we will get in clinical studies. I think if there is a statistically significant difference, but it is not clinically meaningful, I think it will be difficult to have reimbursement…at this time. The drug can be approved, but the reimbursement, access to the market, will be more difficult to obtain for the company.”

OUS KOL, March 2013

“There [has] been a big backlash in the lung cancer world against Avastin most recently … that is a drug that probably has a modest impact and one that is quite expensive and also which has a pretty good rate of complication. So I think we are looking for drugs that are effective which don’t have a high rate of complication and if something meets those standards we will use it.”

US KOL, February 2013

“We have the problem with the testing in some cases you don’t have so much tissue you need to re-biopsy the patients to do further testing … It would be great to have an upfront testing for about 10 to 20 alterations, so you have the information at the beginning of the treatment with the limited tissue you have.”

OUS KOL, March 2013
# Table of Contents

## 1 Table of Contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Title</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Table of Contents</td>
<td>4</td>
</tr>
<tr>
<td>1.1</td>
<td>List of Tables</td>
<td>7</td>
</tr>
<tr>
<td>1.2</td>
<td>List of Figures</td>
<td>7</td>
</tr>
<tr>
<td>2</td>
<td>Introduction</td>
<td>8</td>
</tr>
<tr>
<td>2.1</td>
<td>Catalyst</td>
<td>8</td>
</tr>
<tr>
<td>2.2</td>
<td>Related Reports</td>
<td>8</td>
</tr>
<tr>
<td>2.3</td>
<td>Upcoming Related Reports</td>
<td>11</td>
</tr>
<tr>
<td>3</td>
<td>Disease Overview</td>
<td>12</td>
</tr>
<tr>
<td>3.1</td>
<td>Etiology and Pathophysiology</td>
<td>12</td>
</tr>
<tr>
<td>3.1.1</td>
<td>Etiology</td>
<td>12</td>
</tr>
<tr>
<td>3.1.2</td>
<td>Pathophysiology and Histology</td>
<td>12</td>
</tr>
<tr>
<td>3.1.3</td>
<td>NSCLC Biomarkers</td>
<td>13</td>
</tr>
<tr>
<td>3.1.4</td>
<td>Quality of Life</td>
<td>14</td>
</tr>
<tr>
<td>3.2</td>
<td>Symptoms</td>
<td>15</td>
</tr>
<tr>
<td>4</td>
<td>Disease Management</td>
<td>17</td>
</tr>
<tr>
<td>4.1</td>
<td>Treatment Overview</td>
<td>17</td>
</tr>
<tr>
<td>4.1.1</td>
<td>Diagnosis</td>
<td>19</td>
</tr>
<tr>
<td>4.1.2</td>
<td>Clinical Staging</td>
<td>19</td>
</tr>
<tr>
<td>4.1.3</td>
<td>Screening and Early Detection</td>
<td>22</td>
</tr>
<tr>
<td>4.1.4</td>
<td>Localized Procedures and Therapies</td>
<td>23</td>
</tr>
<tr>
<td>4.1.5</td>
<td>Systemic Chemotherapy</td>
<td>24</td>
</tr>
</tbody>
</table>
# Table of Contents

4.1.6 Targeted Therapy .................................................................................................................. 25

5 Competitive Assessment ............................................................................................................. 28
  5.1 Overview .................................................................................................................................. 28
  5.2 Strategic Competitor Assessment ............................................................................................ 29

6 Opportunity and Unmet Need ..................................................................................................... 32
  6.1 Overview .................................................................................................................................. 32
  6.2 Improved Overall Survival and Less Toxicity ........................................................................... 33
  6.3 Treatments for Patients with Acquired TKI Resistance .............................................................. 34
  6.4 Better Treatment Options for Squamous Patients ...................................................................... 35
  6.5 Preventing Relapse or Recurrence ........................................................................................... 35
  6.6 More Efficacious Second-Line Therapies ................................................................................ 36
  6.7 Increased Availability of Mutation Testing ................................................................................ 36
  6.8 More Cost-Effective Therapies .................................................................................................. 37
  6.9 Unmet Needs Gap Analysis ..................................................................................................... 38

7 Pipeline Assessment ................................................................................................................... 42
  7.1 Overview .................................................................................................................................. 42
  7.2 Promising Drugs in Clinical Development .............................................................................. 42

8 Ganetespib (STA-9090) ............................................................................................................... 46
  8.1 Overview .................................................................................................................................. 46
  8.2 Efficacy ..................................................................................................................................... 47
  8.3 Safety ........................................................................................................................................ 49
  8.4 Dosing and Formulation .......................................................................................................... 49
  8.5 Potential Clinical Positioning .................................................................................................... 49
# Table of Contents

8.6 Potential Commercial Positioning...........................................................................51
8.7 Pricing and Reimbursement..................................................................................52
8.8 SWOT Analysis......................................................................................................52
8.9 Forecast................................................................................................................53

9 Appendix.................................................................................................................55

9.1 Bibliography........................................................................................................55
9.2 Abbreviations.......................................................................................................60
9.3 Methodology........................................................................................................63
9.4 Forecasting Methodology....................................................................................63
  9.4.1 Number of NSCLC Patients Currently Seeking Treatment.............................63
  9.4.2 Percent Drug-treated Patients..........................................................................64
  9.4.3 General Pricing Assumptions............................................................................64
  9.4.4 Individual Drug Assumptions...........................................................................67
  9.4.5 Generic Erosion...............................................................................................67
  9.4.6 Pricing of Pipeline Agents................................................................................67
9.5 Physicians and Specialists Included in This Study .............................................68
9.6 Survey of Prescribing Physicians.........................................................................70
9.7 About the Authors...............................................................................................71
  9.7.1 Author............................................................................................................71
  9.7.2 Epidemiologist...............................................................................................71
  9.7.3 Global Head of Healthcare............................................................................72
9.8 About GlobalData..................................................................................................73
9.9 Disclaimer..............................................................................................................73
1.1 List of Tables

Table 1: Symptoms of Disease NSCLC ................................................................. 16
Table 2: Treatment Guidelines for NSCLC .......................................................... 18
Table 3: Stage Definitions for NSCLC ................................................................. 21
Table 4: Treatment Overview by Stage of Diagnosis for NSCLC ......................... 27
Table 5: Leading Treatments for NSCLC ............................................................ 31
Table 6: Overall Unmet Needs – Current Level of Attainment .......................... 33
Table 7: Clinical Unmet Needs – Gap Analysis, 2013 ....................................... 39
Table 8: Non-Small Cell Lung Cancer – Phase I-II Pipeline, 2013 ..................... 43
Table 9: NSCLC – Phase III Pipeline, 2013 ....................................................... 44
Table 10: NSCLC – Advantages and Disadvantages of Therapeutic Classes ....... 45
Table 11: Product Profile – ganetespib (STA-9090) ........................................... 47
Table 12: ganetespib SWOT Analysis, 2013 ..................................................... 52
Table 13: Global Sales Forecasts ($m) for ganetespib, 2012-2022 ..................... 54
Table 14: Five Year Prevalence ......................................................................... 64
Table 15: Physicians Surveyed by Country ....................................................... 70

1.2 List of Figures

Figure 1: Competitive Assessment of Late-Stage Pipeline Agents in NSCLC, 2012–2022 .................................................. 45
2 Introduction

2.1 Catalyst

Non-small cell lung cancer (NSCLC) is the second most common cancer in both men and women. Diagnosed patients have an extremely poor prognosis, with five-year survival rates limited to approximately 2% in US patients diagnosed at stage IV of the disease. Historically, treatment options for advanced-stage NSCLC patients have been dominated by platinum-based chemotherapy. However, the launch of targeted therapies such as Iressa (gefitinib) in 2003, Tarceva (erlotinib) in 2004 and Xalkori (crizotinib) in 2011 for specific molecular subpopulations of NSCLC patients has revolutionized the treatment landscape. During the forecast period, the competitive landscape will continue to evolve as new targeted therapies are launched that address specific biomarkers or histology in the first and second lines of therapy. The NSCLC market will continue to grow during the forecast period, driven by a rising aging population and increasing incident cases of NSCLC in the US, 5EU, Japan, China and India.

In addition, the launch of emerging premium-priced pipeline agents will drive the uptake of new therapies and prolong the time of patients on therapy in the second line and beyond. Physicians will have several treatment options to choose from to address the high unmet needs of their NSCLC patients, including Gilotrif and LDK378 for the treatment of patients who develop resistance to first-line treatment with epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) therapies, and necitumumab for the first-line treatment of squamous NSCLC patients. In addition, launch of the first-in-class PD1 immunotherapy, nivolumab, will be a significant contributor to market growth during the forecast period.

2.2 Related Reports

"Non-small cell lung cancer (NSCLC) is the second most common cancer in both men and women. Diagnosed patients have an extremely poor prognosis, with five-year survival rates limited to approximately 2% in US patients diagnosed at stage IV of the disease."
Introduction

- GlobalData (2013). Non-Small Cell Lung Cancer - Italy Drug Forecast and Market Analysis to 2022. GDHC1127CFR
- GlobalData (2013). Alimta (Non-Small Cell Lung Cancer) - Forecast and Market Analysis to 2022. GDHC195DFR
- GlobalData (2013). Abraxane (Non-Small Cell Lung Cancer) - Forecast and Market Analysis to 2022. GDHC196DFR
- GlobalData (2013). Iressa (Non-Small Cell Lung Cancer) - Forecast and Market Analysis to 2022. GDHC197DFR
- GlobalData (2013). Tarceva (Non-Small Cell Lung Cancer) - Forecast and Market Analysis to 2022. GDHC198DFR
Introduction

- GlobalData (2013). Xalkori (Non-Small Cell Lung Cancer) - Forecast and Market Analysis to 2022. GDHC199DFR
- GlobalData (2013). Avastin (Non-Small Cell Lung Cancer) - Forecast and Market Analysis to 2022. GDHC200DFR
- GlobalData (2013). onartuzumab (Non-Small Cell Lung Cancer) - Forecast and Market Analysis to 2022. GDHC201DFR
- GlobalData (2013). necitumumab (Non-Small Cell Lung Cancer) - Forecast and Market Analysis to 2022. GDHC202DFR
- GlobalData (2013). ramucirumab (Non-Small Cell Lung Cancer) - Forecast and Market Analysis to 2022. GDHC203DFR
- GlobalData (2013). custirsen (Non-Small Cell Lung Cancer) - Forecast and Market Analysis to 2022. GDHC204DFR
- GlobalData (2013). nintedanib (Non-Small Cell Lung Cancer) - Forecast and Market Analysis to 2022. GDHC206DFR
- GlobalData (2013). Gilotrif (afatinib) (Non-Small Cell Lung Cancer) - Forecast and Market Analysis to 2022. GDHC207DFR
- GlobalData (2013). dacomitinib (Non-Small Cell Lung Cancer) - Forecast and Market Analysis to 2022. GDHC208DFR
- GlobalData (2013). LDK 378 (Non-Small Cell Lung Cancer) - Forecast and Market Analysis to 2022. GDHC209DFR
- GlobalData (2013). Yervoy (Non-Small Cell Lung Cancer) - Forecast and Market Analysis to 2022. GDHC210DFR
- GlobalData (2013). nivolumab (Non-Small Cell Lung Cancer) - Forecast and Market Analysis to 2022. GDHC211DFR
- GlobalData (2013). GSK1572932A (MAGE-A3) (Non-Small Cell Lung Cancer) - Forecast and Market Analysis to 2022. GDHC212DFR
Introduction

- GlobalData (2013). Halaven (Non-Small Cell Lung Cancer) - Forecast and Market Analysis to 2022. GDHC213DFR
- GlobalData (2013). Non-Small Cell Lung Cancer - Current and Future Players. GDHC1017FPR

2.3 Upcoming Related Reports

Appendix

9.8 About GlobalData

GlobalData is a leading global provider of business intelligence in the healthcare industry. GlobalData provides its clients with up-to-date information and analysis on the latest developments in drug research, disease analysis, and clinical research and development. Our integrated business intelligence solutions include a range of interactive online databases, analytical tools, reports, and forecasts. Our analysis is supported by a 24/7 client support and analyst team.

GlobalData has offices in New York, Boston, London, India, and Singapore.

9.9 Disclaimer

All Rights Reserved.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form by any means, electronic, mechanical, photocopying, recording, or otherwise, without the prior permission of the publisher, GlobalData.